Rolls-Royce stock jumps 15% – could it climb further?
Aircraft-engine group Rolls-Royce’s CEO has been hailed as a hero for spearheading the firm’s recovery. And the future looks bright, says Matthew Partridge


Aircraft engine maker Rolls-Royce declared in February that it would hit its profit targets two years early, says Philip Georgiadis in the Financial Times. The stock promptly bounced 15%, making it one of the ten biggest in the FTSE 100.
Rolls-Royce’s latest results, which included a 13% rise in the order book for new engines, “underlined the scale of the recovery... since governments shut the skies during the pandemic”.
It also announced that it would launch a £1 billion share buyback, in addition to bringing back a dividend of 6p a share, as promised last year.
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE

Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Many of Rolls-Royce’s past problems were due to its slow recovery from Covid, which had “brought it to its knees”, says Robert Lea in The Times. However, the real turning point came when CEO Tufan Erginbilgic arrived in 2023 and worked hard on “changing the mindset” of the company’s staff.
He managed to persuade them to focus on “the strategic progress required both every day and for the long term”. He has also “transformed” the profitability of Rolls-Royce by renegotiating existing contracts and improving the value of new deals.
What's behind Rolls-Royce's financial turnaround?
Erginbilgic’s leadership is a “case study for reviving a moribund industrial icon”, say Bloomberg’s Kate Duffy and Anthony Palazzo.
He has made “shrewd decisions”, including “selling off a division dedicated to electric flight, as well as shutting down development efforts for fuel cells and advanced air-mobility craft such as air taxis”.
His “zero-based budgeting” and decision to “give everyone... clear... responsibilities” has cut waste and bureaucracy at a company that once “flew three employees to southern France to erect a company sign”.
Despite Rolls-Royce’s success, there are still “problems on the horizon” for the CEO to navigate, says Matt Oliver in The Telegraph. It has recently “taken heat” from airlines after problems with its troubled Trent 1000 resurfaced.
BA has been forced to cancel flights because of “excessive wear and tear to the engines” that power its fleet of Boeing 787 Dreamliner jets. Rolls-Royce has been forced to admit that it has “struggled to keep pace with the need for replacement engines and parts – causing some aeroplanes to remain grounded”. It even warns that difficulties with the supply chain, which have constrained deliveries, could last for up to 18 months.
Yet “it’s hard to dispute that Rolls-Royce finds itself in multiple sweet spots”, says Nils Pratley in The Guardian. For instance, small modular reactors should (finally) get the go-ahead soon, and the power-systems business “can expect a new class of customer in the form of data centres”.
The defence division had been “nicely supported by the Aukus (Australia-UK-US) submarine partnership even before governments’ boost to military spending”.
Finally, there is also Rolls-Royce’s re-entry into the market for engines for narrowbody aeroplanes, probably sometime in the next decade, for investors to look forward to.
This article was first published in MoneyWeek's magazine. Enjoy exclusive early access to news, opinion and analysis from our team of financial experts with a MoneyWeek subscription.
Sign up for MoneyWeek's newsletters
Get the latest financial news, insights and expert analysis from our award-winning MoneyWeek team, to help you understand what really matters when it comes to your finances.
Matthew graduated from the University of Durham in 2004; he then gained an MSc, followed by a PhD at the London School of Economics.
He has previously written for a wide range of publications, including the Guardian and the Economist, and also helped to run a newsletter on terrorism. He has spent time at Lehman Brothers, Citigroup and the consultancy Lombard Street Research.
Matthew is the author of Superinvestors: Lessons from the greatest investors in history, published by Harriman House, which has been translated into several languages. His second book, Investing Explained: The Accessible Guide to Building an Investment Portfolio, is published by Kogan Page.
As senior writer, he writes the shares and politics & economics pages, as well as weekly Blowing It and Great Frauds in History columns He also writes a fortnightly reviews page and trading tips, as well as regular cover stories and multi-page investment focus features.
Follow Matthew on Twitter: @DrMatthewPartri
-
Is the UK heading for a recession?
Trump’s tariffs have caused a pronounced stock market downturn as global growth expectations fall. Could trade disruption push the UK into recession?
By Dan McEvoy Published
-
Review: Constance Lemuria and Ephelia – two Indian Ocean idylls
Ruth Emery visits Constance Lemuria and Constance Ephelia in the Seychelles for sun, sea and some of the best sushi she has ever had
By Ruth Emery Published
-
Best of British bargains: cash in on undervalued companies in the UK stock market
Opinion Michael Field, Chief Equity Market Strategist, EMEA, Morningstar, selects three attractive UK stocks where he'd put his money
By Michael Field Published
-
Building firm Keller presents low debt and ample scope for growth
Geotechnical contractor Keller, which supports vital global infrastructure, boasts rising profits and a cheap valuation
By Dr Mike Tubbs Published
-
PZ Cussons share price down 75% in last decade – why it's one to watch
Opinion Once-strong consumer-goods business PZ Cussons is out of favour with the market. That spells opportunity for investors, says Jamie Ward
By Jamie Ward Published
-
Cash in on the biotech sector with specialist trust BioPharma
Opinion BioPharma has an attractive niche in lending to asset-rich biotechnology companies
By Rupert Hargreaves Published
-
India's stock market decline wipes out $1.3 trillion in market value – can investors stay optimistic?
More than $1 trillion has been wiped off from India's stock market after investors turn to China. Has the emerging-market darling hit rock bottom?
By Alex Rankine Published
-
Pensions revolution: how to profit from the trends shaping the UK pension system
The UK pension system is one of the biggest in the world. Big changes are under way, says Rupert Hargreaves
By Rupert Hargreaves Published
-
Large cap stocks start to struggle – is it time for investors to reassess their focus?
Buying quality large caps worked very well last decade. A more volatile world will be a bigger challenge for these star stocks, says Cris Sholto Heaton
By Cris Sholto Heaton Published
-
How to generate income with fixed-interest investments
Public debt is overvalued, but other fixed-interest investments now look like a bargain, says Max King
By Max King Published